Chang H, Rockman CB, Cayne CS, et al. - Researchers aimed at determining the correlation between chronic anticoagulation/antiplatelet medications and aortic remodeling of patients with type B thoracic dissection (TBAD) after thoracic endovascular aortic repair (TEVAR). Reviewing records of the Vascular Quality Initiative TEVAR registry (2011-2019), they identified 1,507 patients (mean age, 60.7 ± 12.2 years; 68.3% male) with a mean follow-up of 18.9 ± 13.7 months. Of these, 201 (14%) patients were on anticoagulation therapy at follow-up. Outcomes revealed no adverse effect of the chronic use of anticoagulation and antiplatelet medications on the rate of complete false lumen thrombosis and positive aortic remodeling in patients who underwent TEVAR for TBAD. Hence, they suggest that in these patients, anticoagulation and antiplatelet medications may be safely used.